Solasodine reverses stemness and epithelial-mesenchymal transition in human colorectal cancer

26Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Adverse side effects of conventional chemotherapy, acquired resistance and fatal tumor metastasis of human colorectal cancer (CRC) are propelling the exploration for novel selective anticarcinogens. Solasodine is a main active component isolated from Solanum incanum L that exhibited a potent stemness and invasion inhibitory effect on human colorectal cancer HCT116 cells. Colony Spheroid formation assay showed that solasodine dose-dependently prohibited HCT116 cell stemness. CD133, CD44, Nanog, Oct-4 and Sox-2 were inhibited by solasodine to reverse stemness and similar mechanism was stimulated in vivo. Transwell and scratch wound assays revealed that solasodine impeded HCT116 cell invasion and migration potential strengthened by TGF-β1. Moreover, solasodine attenuated TGF-β1-induced EMT and decreased MMPs while in vivo study showed the same trend. The results of this study implied that solasodine may be a novel therapeutic drug for CRC treatment.

Cite

CITATION STYLE

APA

Zhuang, Y. wen, Wu, C. en, Zhou, J. yong, Zhao, Z. ming, Liu, C. li, Shen, J. yi, … Liu, S. lin. (2018). Solasodine reverses stemness and epithelial-mesenchymal transition in human colorectal cancer. Biochemical and Biophysical Research Communications, 505(2), 485–491. https://doi.org/10.1016/j.bbrc.2018.09.094

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free